Compare Ginkgo Bioworks Holdings Inc (DNA) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs MINISO Group Holding Ltd — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while MINISO Group Holding Ltd trades at $12.37 (market cap $3.46B). The key difference: MINISO Group Holding Ltd is far larger — about 5.9× Ginkgo Bioworks Holdings Inc's market cap, and MINISO Group Holding Ltd pays a 5.78% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | MNSO | |
|---|---|---|
Market Cap | $590.53M | $3.46B |
Sector | Health | Technology |
52-Week High | $16.14 | $26.63 |
52-Week Low | $5.48 | $11.30 |
Enterprise Value | $627.78M | $4.13B |
Dividend Yield | — | 5.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
MNSO trades at $11.42, down 3.14% on the day, reflecting recent volatility. The stock shows mixed signals with a bearish technical trend but solid fundamentals, including a P/E of 11.73 and net income margin of 8.98%. Recent corporate actions include a $0.38 dividend and a HK$2 billion share repurchase program announced on June 29, 2026, signaling management confidence. Q1 2026 earnings beat expectations with EPS of $0.591 versus $0.238 expected, though prior quarters missed estimates.
Outlook is cautiously optimistic given strong profitability metrics and shareholder-friendly actions, but risks include margin pressures from overseas expansion and technical bearishness. With 75% analyst buy ratings and an undervalued GF Score per GuruFocus on June 29, 2026, the stock offers value if execution improves, though investors should monitor earnings consistency and global economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
